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(57) ABSTRACT 
A device for use in the total cavopulmonary connection 
(TCPC) in order to optimize its hemodynamics. Although the 
current procedure of choice for single ventricle heart repairs, 
the TCPC has reduced the post-operative mortality to the 
level of simpler types of congenital heart disease repairs, 
Fontan patients are still subjected to serious long-term com-
plications. The TCPC procedure, which restores the vital 
separation between oxygenated and deoxygenated blood, 
also leads to an increased workload for the remaining single 
ventricle, as it is now responsible for pumping the blood 
through both the systemic and pulmonary circulation. The 
present device reduces this workload by altering the surgi-
cally created design of the TCPC. Improved fluid mechanics 
and reduced energy dissipation at the connection site trans-
lates into less work for the single ventricle and improved 
transport of deoxygenated blood to the lungs, which may in 
turn contribute to improved post-operative results and quality 
oflife. 
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R sys = 17.5 mmHg/L/rnin 
(a) Normal Circulation (b) Congenital Defects 
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This application is a US National Stage of International 
Application No. PCT/US2005/009835 filed 23 Mar. 2005, 
which claims the benefit ofU.S. Ser. No. 60/555,515, filed 23 
Mar. 2004. 
GOVERNMENT INTERESTS 
This invention was made in part during work supported by 
the U.S. Government, including grants from the National 
Institutes of Health (NIH) HL67622-01Al. The government 
may have certain rights in the invention. 
BACKGROUND OF THE INVENTION 
1. Field of the Invention 
This invention relates generally to a junction device for a 
plurality of flows, and more specifically to an anatomical or 
surgically created connection. 
2. Description of Related Art 
The incidence among other congenital heart defects of 
children born in the USA with complex congenital heart 
defects in which there is only one effective pumping chamber 
is about 20%. Some studies indicate that the overall incidence 
of congenital heart defects is 1 %-and therefore, generally 
two babies per 1000 births will be born with a single ventricle. 
If untreated, life expectancy can be short. 
Surgical repairs that separate the pulmonary and systemic 
circuits, placing them in series with the univentricular pump, 
termed "Fontan Repairs," are palliative, and unfortunately not 
curative. Operations are routinely staged over many years and 
survivors often require a lifetime (rather limited) of intensive 
medical attention. Cardiologists report that their patient 
populations with this complex cardiovascular physiology 
(approximately 20%) require a disproportionate share of their 
time (at least 50%). 
The concept of a total right ventricular bypass, first intro-
duced by Fon tan and Baudet in 1971, is a palliative procedure 
aimed at separating the systemic and pulmonary circulations, 
thus eliminating mixing of oxygenated and deoxygenated 
blood. The remaining left ventricle drives the blood flow 
throughout the entire body. 
Since its inception, modifications of the Fontan procedure 
have steadily improved surgical outcomes, reducing the post-
operative mortality to the level of more simple types of con-
genital heart disease repairs. However, the marked improve-
ment in surgical outcome is balanced by the numerous and 
serious long-term complications encountered by the Fontan 
patients, such as ventricular dysfunction, thromboembolism, 
arrhytmias and protein loss enteropathy. 
As a general background, in the cardiovascular system, 
blood is a major means of transportation for the nutrients and 
wastes that travel to and from the body's tissues. It is pumped 
through the entire body by the heart, and then perfuses each 
single tissue through a complex network of arteries, capillar-
ies and veins. The cardiovascular circulation can be subdi-
vided into two primary circuits: the pulmonary and systemic 
circulations. The pulmonary circuit describes the path going 
from the heart to the lungs and back, and the systemic circu-
lation transports the blood between the heart and the remain-
der of the body. 
The normal heart has four chambers: the left and right atria 
and the left and right ventricles. In a normal physiology the 
septum separates the left and right sides of the heart creating 
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two distinct pumps that function in parallel. The left side of 
the heart drives the blood through the systemic circuit, while 
the right side drives the blood through the pulmonary circuit. 
This four-chambered structure of the heart is essential to its 
function. The ventricles provide the pumping force, while the 
atria provide the buffer volume needed to receive the continu-
ous blood flow returning from the body or the lungs. In 
addition to these four chambers, four valves control the inlet 
and outlet of both ventricles to prevent blood-flow reversal 
10 and ensure the efficiency of the ventricular contraction. When 
the left ventricle contracts during systole, the increase in 
ventricular pressure closes the bileaflet mitral valve and 
forces the trileaflet aortic valve open. Consequently, most of 
the blood that was present in the left ventricle before systolic 
15 contraction must flow from the left ventricle through the open 
aortic valve into the aorta then to the rest of the body. 
Meanwhile, the blood returning from the lungs through the 
pulmonary veins is stored in the left atrium. As pressure 
builds up in the left atrium and in the aorta and decreases in 
20 the left ventricle during diastole, the mitral valve reopens and 
the aortic valve closes. Blood then flows from the left atrium 
through the mitral valve into the left ventricle. 
Similarly, the systemic blood coming back from the body 
flows through the inferior vena cava (IVC) and superior vena 
25 cava (SVC) into the right atrium. It then passes through the 
tricuspid valve into the right ventricle from where it is dis-
charged through the trileaflet pulmonary valve into the pul-
monary circulation for gas exchange. 
Congenital heart defects (CHDs) describe all abnormali-
30 ties of the heart orofthe great arteries (pulmonary arteries and 
aorta) that are present at birth. They are the leading cause of 
infant mortality in the western world accounting for about 
20% of all infant death. CHDs alone account for one-third of 
all birth defects affecting one in every 100 infants in the 
35 United States. They are the number one cause of birth defect 
related deaths during the first year oflife, and the mortality of 
these children may be as high as 50% depending on the 
condition. 
CHDs arise from faulty embryogenesis between the third 
40 and eighth week of gestation, when major cardiovascular 
structures develop-going from a simple straight tube to a 
complex four-chambered heart with separate pulmonary and 
systemic circuits. Over35 different forms ofCHDs have been 
reported, and although the exact cause of CHDs is still 
45 unknown in most cases, multifactorial genetic and environ-
mental parameters, including chromosomal defects, viruses, 
chemicals and radiation are suspected. 
Among all CHDs, particularly challenging are the defects 
(or combination of defects) observed in about 20% of the 
50 CHD cases that effectively lead to a single ventricle (SV) 
anatomy. This physiology results in communication between 
the systemic and pulmonary circulation, thereby eliminating 
the two-pump system and allowing for the mixing of oxygen-
ated and deoxygenated blood. It is well understood that 
55 venous blood mixing should be avoided, and corrected if 
possible. 
FIG.1 is a schematic showing differences between normal, 
single ventricle, and Fontan physiology. In a normal physiol-
ogy, the vena cavae contains deoxygenated blood coming 
60 from the systemic circulation and the pulmonary arteries 
carries the deoxygenated blood from the right ventricle to the 
lungs for the blood to become oxygenated. 
The single ventricle physiology pumps high pressure blood 
to both the systemic and the pulmonary circulation. The high 
65 pressure in the pulmonary circulation and the mixing of oxy-
genated and deoxygenated blood causes many of problems, 
which is why the Fontan procedure is performed. The current 
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Fontan surgical procedure of choice for patients with single 
ventricle physiology is the total cavopulmonary connection 
(TCPC). 
The most prevalent CHDs leading to a SV anatomy include 
multiple ventricular and/or atrial septa! defects, tricuspid 
atresia, hypoplastic left or right heart syndrome, transposition 
of the great arteries, and a double inlet ventricle. 
Without surgical intervention, survival of patients with 
blocked right or left heart pathways as a result of a transpo-
sition of the great arteries, a tricuspid atresia or an acute 10 
hypoplastic heart syndrome once depended on the presence 
of coexisting defects such as a septa! defect or a patent ductus 
arteriosus. In the middle of the 20'h century, surgical shunt 
procedures were developed as a palliative procedure for cyan-
otic CHD. The purpose was to connect the pulmonary arteries 15 
(PAs) with the systemic arteries or with the SVC so as to try 
and augment the pulmonary blood flow. 
These shunts enabled short-term survival. However, ven-
tricular dysfunction, pulmonary vascular disease, and chronic 
cyanosis prohibited a normal existence and drastically short- 20 
erred patient life expectancies with only few patients surviv-
ing beyond adolescence. 
The advent of the Fontan operation in 1971 brought about 
a revolution in the management of single ventricle heart 
defects. In a Fontan type circulation, the left ventricle pumps 25 
blood into the aorta and arteries. This blood flows at first 
rapidly into the different organs. The very same force pushes 
the blood across capillaries, and through the veins. But by its 
very nature, this flow depends on many factors. For instance, 
if the blood vessels in the lung are thick walled and narrow 30 
before surgery, they will offer very high resistance to passive 
blood flow. In such a state, the Fontan operation carmot be 
performed, or will have a high risk of failure, since the extra 
energy needed to maintain lung blood flow is not available. 
Even normally some amount of resistance will exist across 35 
the lung blood vessels. After a Fontan operation, the pressure 
in the veins will therefore be higher than normal, in order to 
overcome this resistance and maintain lung blood flow. The 
elevated pressure in the veins has a few ill effects, including 
that there may be swelling of the entire body due to fluid from 40 
the blood leaking out of the vein walls, there may be facial 
puffiness, fluid accumulation in the abdomen (ascites) or 
chest (pleural effusion), and sometimes even absorption of 
nutrients from the intestines is affected. 
Indeed, the heart may eventually fail. The age at which the 45 
heart fails and the patient requires a heart transplant depend 
on many different factors, but a main reason appears to be the 
excessive workload placed on the single ventricle. The major 
causes of death are: heart failure, arrhythmia, protein losing 
enteropathy, and embolisms. 50 
The principle of a complete right heart bypass, where the 
systemic veins were directly connected to the pulmonary 
arteries without going through the single ventricle, achieved a 
number of salutary transformations to the SV anatomy. It 
re-separated the systemic and pulmonary circuits and elimi- 55 
nated venous blood mixing, which in tum ostensibly 
improved arterial oxygen saturation and patient color. 
The original Fontan procedure included the construction of 
two independent VC-to-PA tracks, the IVC-to-LPA and SVC-
to-RPA, with the anastomosis of the right atrium directly onto 60 
the PAs and a valve placed in the IVC. 
However, it soon became clear that placing a valve in the 
caval conduits, rather than being advantageous, resulted in 
obstruction of the low-pressure VC-to-PA circulation. Fur-
thermore, the separation of the IVC-to-LPA and SVC-to-RPA 65 
tracks, that had been designed to ensure an even perfusion of 
the right and left lungs, did not allow for any adaptation of the 
4 
LPA/RPA blood flow ratio, leading to serious complications 
when one of the pulmonary tracks became obstructed. Addi-
tionally, such a cardiovascular configuration excluded all 
hepatic blood flow from the RPA, which was demonstrated to 
be strongly correlated with pulmonary venous malforma-
tions. 
Shortly after the first successful right ventricular heart 
bypass operation for tricuspid atresia, a modified Fontan pro-
cedure was demonstrated wherein the entire venous return 
could be diverted to the pulmonary circulation through a 
single valveless atria-pulmonary (AP) connection. This pro-
cedure had the combined advantages of providing the pulsa-
tile action of the atrium, redistributing the hepatic fluid to both 
lungs and splitting the pulmonary blood flow depending upon 
the needs and resistance of either lung. 
The valveless AP-connection was the first in a series of 
modifications of the original Fontan procedure. Although this 
procedure was quickly endorsed and has had widespread use 
in many centers, the long-term follow-up of patients with an 
AP-connection indicated that they were prone to late compli-
cations. Patients developed supraventricular arrhytmias, right 
atrial thrombus, exercise intolerance and other symptoms of 
low cardiac output. These complications were usually related 
to a markedly dilated right atrium appendage, which was 
suspected to be due to the increased pressure load imposed on 
the atrium. This atrial dilatation was in tum associated with 
stagnant flows along the dilated right side of the atrium and 
turbulent flows elsewhere in the connection, resulting in sig-
nificant fluid energy dissipation. 
The high incidence of right-atrium related complications 
led many to question the role of the pulsating right atrium and 
its actual contribution to the Fontan circulation. There was in 
vitro and in vivo evidence that the interposition of a passive 
chamber with impaired systolic function between the VCs 
and PAs was a major cause of flow inefficiency, and the total 
cavopulmonary connection was proposed as a logical alter-
native to the Fontan procedure. 
The TCPC has been described as the anastomosis of the 
SVC directly onto the RPA followed by the creation of a 
tunnel through the right atrium connecting the IVC to the 
inferior aspect of the RPA. This geometry has been demon-
strated to lead to more streamlined flow patterns with less 
turbulence and fluid energy loss when compared to the AP-
connection. These findings were confirmed both by in vitro 
and computational fluid dynamic studies. Retrospective clini-
cal studies also investigated early and late mortality rates. 
Findings show that the TCPC is accompanied by a lower 
mortality rate, improved outcomes and a more favorable 
course during the postoperative period. 
Staging the operations has markedly improved surgical 
outcomes, and allowed the Fontan surgery to be applied to a 
larger range of SY-patients. It is now an integral part of the 
methodology for SV heart repairs. Usually, there are three 
different stages involved in the completed "Norwood proce-
dure" leading to the resultant Fontan-each stage with inher-
ent morbidity and associated mortality. 
The first stage is commonly performed immediately after 
birth or within the first two weeks of life and is referred to as 
the first stage Norwood or Norwood I procedure. It involves 
creation of a systemic to pulmonary arterial connection, arch 
reconstruction and coarctation repair with anastamosis of the 
native aorta to the pulmonary arterial trunk (also called the 
Damns-Stancil-Kaye procedure) and an atrial septectomy. 
A more recent modification, the "Sano" procedure, 
involves placement of a right ventricle to pulmonary arterial 
connection and elimination of the systemic to pulmonary 
arterial shunt. 
US 7,811,244 B2 
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The second stage bi-directional "Glenn" procedure (Nor-
wood II), performed at approximately three to four months of 
age, involves anastamosis of the superior vena cavae to the 
pulmonary arteries and removal of the systemic to pulmonary 
shunt or the RV to PA shunt and has the lowest reported risk. 
The last stage (Norwood III), or Fontan procedure is cre-
ation of a connection of the inferior vena cavae to the pulmo-
nary arteries via an intra-atrial or extra-cardiac connection. 
This results in the total cavopulmonary connection. 
6 
As used in FIG. 2, pu is a pulmonary bed (lungs); sys is a 
systemic bed (upper and lower body combined); PDA is the 
patent ductus arteriosus; Ci) illustrates the flow restriction at 
aorta; arrows represent the blood flow directions and cardiac 
shunts; R,r, is the tricuspid valve resistance; Rpulv is the pul-
monary valve resistance; Rm, is the mitral valve resistance; 
and, Rao is the aortic valve resistance. 
Constant representative resistance values are used, 
although it will be understood by those of skill in the art that 
Although most surgeons agree on the staged TCPC as 
being the current procedure of choice for Fontan repairs, 
controversies exist about the selection of the connection type, 
the type of material to use, the need for fenestration, and the 
timing of the operations. 
10 vascular resistances are regulated to some extent by the body 
in response to blood pressure, the changing oxygen saturation 
during exercise, and vary slightly with flow pulsatility. Fur-
ther, newborn children have higher pulmonary resistance val-
ues. 
An average blood flow rate (i.e. cardiac output) for normal 
adults at rest is 5 Umin. For children with the TCPC, the total 
cardiac output is closer to 3 Umin. Cardiac output can be as 
high as 20 Umin during exercise conditions for normal adults 
and in some athletes it goes even higher. 
The resistances of the right and left hearts are mainly due to 
the resistances of the heart valves which are small (-1.5 
mmHg/Umin) compared to the vascular resistances unless 
there is valve stenosis or other problems. 
As previously explained, one-fifth of congenital heart 
The choice of connection type seems to be dictated by 15 
surgeon preference, each type with pros and cons. When 
compared to intra-atrial tunnels, extra-cardiac conduits pro-
vide numerous advantages including smoother geometries, 
fewer atrial suture lines thus minimizing sinus-node damage, 
and less or no time on the heart- lung machine. On the other 20 
hand they provide no growth potential and may lead to con-
duit stenosis and thromboembolism. Although long-term fol-
low-ups are not yet available, early- and mid-term results for 
extra-cardiac conduits are favorable, especially combined 
with a fenestration in the inferior conduit. 25 defects require a series of complex palliative surgeries which 
result in a single operating ventricle with the pulmonary and 
systemic beds arranged in series, as shown in FIG. 3. This 
configuration results in higher pressures in the systemic bed 
Including a fenestration has been demonstrated to lower 
the systemic venous pressures as well as to improve ventricu-
lar filling, consequently leading to improved cardiac output 
and overall oxygen delivery. While some institutions advo-
cate systematic fenestration, others argue that it should be 30 
used more selectively, balancing the potential benefits against 
the risks and costs of the additional intervention needed to 
close the fenestration. 
with severe clinical consequences. FIG. 3 illustrates single 
ventricle circulation after final stage Fontan surgery. RrcPc is 
the equivalent TCPC resistance calculated from in vitro 
experiments for an intra-atrial patient specific anatomy. 
There are two versions of the TCPC namely, extra-cardiac 
and intra-atrial. Yet, current extra-cardiac and intra-atrial 
Similarly, the material of choice varies from institution to 
institution and patient to patient. Intra-atrial tunnels have 
been built out of polytetetrafluoroethylene (PTFE) patches, 
pericardia! patches and autologous pericardia! patches. 
Extra-cardiac conduits have been constructed using PTFE, 
Dacron, and autologous pericardium flaps. Mid-term results 
have been favorable for all synthetic materials and only short-
term follow-up data (30 months) is available for autologous 
conduits. 
35 TCPC yields high energy losses in the blood flow because of 
the mixing of the blood. FIGS. 4 and 5 shows models of the 
TCPC with a transparent blood analog containing particles 
flowing through the connection. FIG. 4 illustrates an in vitro 
glass model of a "zero" offset TCPC. FIG. 5 illustrates an in 
40 vitro model of a one diameter offset and flared model of a 
Cavopulmonary Connection. 
The two inlets (SVC and IVC) and the two outlets (RPA 
and LPA) are shown in different configurations. As can be 
seen from the two figures, there is a region of the connection 
where there is a high level of venous flow mixing and distur-
bance. Such a region exists as the inlets either present inlet 
flows at 180 degrees from one another, forcing the flows to 
collide head on, before separating toward the two outlets, or 
the inlets do not provide such a direct path of collision, but 
Finally, as to the timing of the operation, the mean age at 
TCPC completion and mean interval since previous palliation 45 
have significantly decreased over the past decade. While 
some see this as a beneficial trend that has reduced most of the 
major complications, others recommend caution pointing out 
that suture lines significantly limit vessel growth and that 
vessel size is a major factor for hemodynamic efficiency. 50 even with offset of some amount, the inlet flows nonetheless 
collide with each other or with a wall sufficiently to present 
outlet flows with marked energy loss. 
Thus, it can be seen that although various cardiac repair 
options are known, there is still much room for improvement. 
Indeed, this should not take away from the success of the 
Fontan procedure. It is simply that connecting the vena cavae 
directly to the lungs, bypassing the heart, is a difficult task for 
the single ventricle due to chronic work and volume overload. 
The region of mixing in present connection designs negates 
the beneficial momentum present in the two inlet flows that 
55 exists before the blood in the IVC and SVC enter the connec-
In FIG. 2(a ), the normal operating circulation with the two 
(left and right ventricles) pumping action of the heart is illus-
trated. The resistance and pressure values shown are repre-
sentative average values for a healthy adult person measured 60 
clinically by catheterization. FIG. 2(a) is a schematic of nor-
mal circulation-lumped representation of pulmonary and 
systemic beds. FIG. 2(b) illustrates various congenital heart 
defects. The systemic vascular resistance (Rsys) is approxi-
mately 17 .5 mmHg/Umin on average, and the pulmonary 65 
vascular resistance (Rpuz) is approximately 1.8 mmHg/Umin 
on average. 
tion site, wherein the momentum loses due to swirling, tur-
bulence, and other collision characteristics, limits the outlet 
flows to the lungs. 
In this mixing region of the connection, there is a lot of 
swirling of the flows, when the blood analogue from the inlets 
mix, which causes substantial energy loss, causing the outlet 
flow to lose momentum towards the lungs via the two outlets. 
This is known disadvantage with the current configurations 
used for Fontan procedures. 
RPA/LPA flow splits of 30/70, 40/60, and 50/50 in the 
models of FIGS. 4 and 5 have shown that when an equal flow 
goes to both the RPA and the LPA, there is the least amount of 
US 7,811,244 B2 
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energy loss in the flow. Furthermore, the energy loss in the 
flow increases the more the vessel diameters in the connection 
are different. Thus, energy loss in the flow is minimized with 
equal flow in the vessels. 
The current Fontan connection typically resembles a mix 
of FIGS. 6 and 7, thus giving rise to substantial energy losses 
due to disadvantageous inlet flow collision. FIG. 6 illustrates 
a one diameter offset planar TCPC model. SVC and IVC 
diameters are more representative of the in vivo dimensions. 
FIG. 7 illustrates a TCPC model incorporating non-planar 10 
arrangement of pulmonary arteries, wherein FIG. 7 (a) shows 
a front view, and FIG. 7(b) a top view of the same connection. 
The FIG. 7 model also incorporates a one diameter caval 
offset; however, all vessels are assumed to be the same size. 
While, experimentally, the model of FIG. 5 shows good 15 
results compared to the others, nutritious blood coming from 
the hepatic veins goes primarily to one lung, increasing the 
size and functionality of this lung compared to the other lung, 
and this is not optimal. 
It is evident that current anatomical connections provide 20 
non-optimal energy loss in the flow at regions of the connec-
tion where there is a high level of venous flow mixing and 
disturbance. There is thus a need for an anatomical connec-
tion providing optimized flow control, equal distribution of 
hepatic blood to both lungs, and minimized energy loss, that 25 
in effect minimizes or elimates inlet flow collision. It is the 
provision of such a connection that the present invention is 
primarily directed. 
8 
inlet flow mixing other than parallel flow stream mixing. The 
preferred connection comprises a two-inlet, two-outlet con-
nection for optimized flow control and reduced fluid energy 
losses. 
The IVC and SVC flow paths are bifurcated, and one each 
of the bifurcated flow paths of the IVC and SVC then rejoined 
with the corresponding path to provide a parallel flow path 
configuration to the outlets. The design characteristics ofthis 
connection used with the two-inlet blood vessels (IVC and 
SVC) and two-outlet blood vessels (RPA and LPA) mini-
mizes disturbance, swirling, stagnation, and stagnant flow, 
resulting in reduced energy loss. Reduction in energy losses is 
desired for several reasons, namely: (1) reduced pressure 
build-up in the blood vessels especially in the abdominal 
region, (2) reduced workload on the left ventricle, (3) 
increased ability of the heart to support activities such as 
running or other exercise. Further, a reduction in the risk of 
thrombus and emboli formation can be had with the present 
invention as it minimizes the amount of flow recirculation and 
stasis. 
The disturbance, swirling, stagnation, stagnant flow, and 
energy loss is reduced in the present invention as each of the 
two inlets bifurcate in two paths, a left path and a right path. 
The left and right paths gently guide the inlet flows through, 
for example, 90 degrees. The connection has a top inlet, a 
bottom inlet, a left outlet, and a right outlet. The top inlet is 
split into a left path and a right path, as is the bottom inlet. 
BRIEF SUMMARY OF THE INVENTION 30 Inlet blood flow from the top inlet that is diverted to the top 
left path is combined with the inlet blood flow from the 
bottom inlet that is diverted to the bottom left path. The two 
left path flows of the original IVC and SVC flows mix with 
Among the multiple variables that determine the outcome 
and the quality oflife of patients with ventricular bypass, one 
that allows for some degree of control is the design of the 
bypass connection. The present invention is a connection 35 
scheme that was developed with a critical review of the hemo-
dynamics/fluid dynamics at the bypass connection site, in 
order to optimize the connection design to minimize momen-
tum loss in the connection as between the inlet flows, and the 
outlet flows. 
vectors of the same bearing, thus limiting momentum loss and 
mixing. 
Similarly, inlet blood flow from the top inlet that is diverted 
to the top right path is combined with the inlet blood flow 
from the bottom inlet that is diverted to the bottom right path. 
Thus, the two right path flows of the original IVC and SVC 
In the total cavopulmonary connection, the inferior venae 
cavae (IVC) and the superior venae cavae (SVC) are anasta-
mosed directly onto the pulmonary arteries (PAs), forming 
for the most part a "plus"/"+" -shaped connection, having two 
inlets approximately 180 degrees from one another, and two 
outlets, also at approximately 180 degrees. See FIG. 4, for 
example. 
40 flows also mix, but with common vectors of travel, thus 
limiting momentum loss. 
It will be understood that at the intersection of the+ design, 
the two inlet flows will collide head on, diffusing much of the 
momentum of the two inlet flows prior to collision, before the 
site of mixing splits into the two outlets. 
The inlet flows in the current design therefore do not meet 
at a site of collision or high disturbance like in present con-
nections, but merge together in at least approximately parallel 
45 flows, providing less flow separation, and a mixing of the IVC 
and SVC blood flow preferably only at the two outlets, not at 
some central region of mixing in the connection. 
The present connection can furthermore be used to control 
50 
inlet, outlet, and path flows by decreasing or increasing the 
vessel diameters. The connection may be fashioned from 
existing blood vessels, graft materials, or a combination of 
both. 
It would be beneficial if a TCPC connection could be 
designed to limit the momentum loss from flow inlet to flow 
outlet. If the region of head-on mixing of the inlet paths of 
present TCPC connections were limited in size, or indeed 55 
eliminated, then a far greater amount of the full momentum of 
the two inlet flows could be directed to the lungs with little 
energy loss from the IVC and SVC flows. 
The present invention is a connection geometry that pro-
vides superior streamlined flow patterns with less disturbance 60 
and fluid energy loss when compared to present connections. 
In other embodiments, the device can be described as limiting 
flow turbulence, unsteadiness, instability, oscillations, or 
unwanted secondary flows. 
Briefly described, in preferred form, the present invention 65 
is an improvement in TCPC hemodynamics and geometry, 
providing a device that in essence eliminates any regions of 
The preferred environment for the present invention are in 
blood vessel connections where there are two inlets and two 
outlets, and optimal flow is desired, as well as some control of 
pressures and flows by changing vessel diameters. The 
present invention is primarily intended for patients with a 
single ventricle who undergoes the Fontan surgery. While the 
connection can be located in the body at the site of the heart, 
it is possible to have in vitro, in vivo and ex vivo connection 
embodiments utilizing the present invention. 
The present invention provides advantages over the con-
ventional connection geometries as it reduces swirling, dis-
turbance, stagnant flow, and by enabling the changing of 
diameters of the vessels, the flow and pressure can be fully 
controlled in all four vessels. 
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These and other objects, features and advantages of the 
present invention will become more apparent upon reading 
the following specification in conjunction with the accompa-
nying drawing figures. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG.1 is a schematic showing differences between normal, 
single ventricle, and Fontan physiology. 
FIG. 2(a) is a schematic of normal circulation. 
FIG. 2(b) illustrates various congenital heart defects. 
FIG. 3 illustrates single ventricle circulation after final 
stage Fontan surgery. 
FIGS. 4 and 5 show models of prior art TCPCs with a 
transparent blood analog containing particles flowing 
through the connection to illustrate mixing and disturbance. 
FIG. 6 illustrates a one diameter offset planar prior art 
TCPCmodel. 
FIG. 7 illustrates a prior art TCPC model incorporating 
anatomically realistic non-planar arrangement of pulmonary 
arteries, wherein FIG. 7(a) shows a front view, and FIG. 7(b) 
a top view of the same connection. 
FIG. 8 is a preferred embodiment of the present invention. 
FIG. 9 is a flow diagram of the embodiment of the present 
invention according to FIG. 8. 
FIG. 10 is another preferred embodiment of the present 
invention. 
FIGS. 11-12 illustrate other embodiments of the present 
invention that have less than either two inlets or two outlets. 
FIG.13 is a flow diagram ofa one inlet, two outlet embodi-
ment of the present invention. 
FIG. 14 is another preferred embodiment of the present 
invention being a bilateral SVC connection. 
FIG. 15 is another embodiment of the device of FIG. 14. 
FIGS. 16-20 are other preferred embodiments of the 
present invention as a center piece device. FIG. 19 illustrates 
the environment of use for the center piece embodiment of the 
present invention of FIG. 18. 
FIG. 21 illustrates computational fluid dynamics (CFD) 
calculations in mid-plane section of a preferred embodiment 
of the present invention showing in-plane velocity magni-
tudes. 
10 
second branch, splitting a second inlet flow at the flow merg-
ing device into a first branch and a second branch, and merg-
ing the first branches of the first and second inlet flows 
together, wherein the flows in each of the first branches are 
substantially parallel at the site of merging. 
The present invention is a flow merging device, designed to 
take what are generally two inlet flows traveling at different 
directions (commonly at approximately 180 degrees from 
one another), and providing a flow combination scheme that 
10 combines the inlet flows not head on, but when they are in the 
same direction of travel. That is, provide outlet flow paths that 
do not require the inlet flows to mix at anything less than 
common vectors of travel. 
In one preferred embodiment of the present invention, the 
15 method and device for use in bypassing the right side of the 
heart, and redirecting the venous blood flow from the sys-
temic to the pulmonary circulation in an energy efficient 
manner, wherein a multiple-inlet, multiple-outlet connection 
is used to bifurcate each of the incoming venous flows, and 
20 appropriately redistribute the split flows to each lung, 
wherein the act of splitting the inlet flows is performed in an 
energy efficient manner, reducing flow resistance, swirl, and 
helicity, as well as the amount of recirculation and flow stasis. 
It will be understood that the present invention can either 
25 foster proper vessel orientation, or can itself provide the path-
ways for blood flow. That is, the invention can be a flow 
merging device wherein vessels are attached to inlet(s) and 
outlet(s), and the flow is within the device, or the present 
invention can be of a center piece construction, such that the 
30 center piece fosters blood flow around itself (as opposed to 
within itself). 
A preferred method of the present invention is a method of 
combining the IVC and SVC flows at zero offset by utilizing 
a device that diverts the incoming IVC and SVC flow streams 
35 before they would normally intersect at a common point of 
collision, and divert them into as close to parallel flows as 
practical before allowing them to smoothly combine, to then 
travel to the lungs. 
The invention preferably comprises a first connection inlet 
40 for inferior vena cava, and a second connection inlet for the 
superior vena cava. Each of the first and the second connec-
tion inlets are themselves bifurcated, such that the desired 
amount of flow of each of the inferior and the superior vena FIG. 22 is an experimental result acquired from particle 
image velocimetry (PIV) measurements in the mid-plane of 
another preferred embodiment of the present invention show- 45 
ing velocity magnitudes of the flow. 
cava are directed to outlets of the device. 
A first connection outlet provides a blood flow path for the 
merging of a desired amount of the inferior vena cava flow, 
and a desired amount of the superior vena cava flow, wherein 
the margining of these two flows is parallel. A second con-
nection outlet provides a blood flow path for the merging of 
FIG. 23 is a graph of the hydrodynamic power loss com-
parisons of a preferred embodiment of the present invention 
against a one diameter offset reference model. 
FIG. 24 is a graph of pressure drop comparisons of a 
preferred embodiment of the present invention against a one 
diameter offset reference model at different cardiac outputs. 
FIG. 25 is a graph comparing pressure drops ( dP) between 
50 the second amount of the inferior vena cava flow, and the 
second amount of the superior vena cava flow. 
The device thus alters the flow combination of the inferior 
a patient-specific reconstruction of a prior art device as 
against the use of a preferred embodiment of the present 55 
vena cava and the superior vena cava from essentially 180 
degrees, to zero degrees, such that instead of the flows col-
liding head on before traveling to the lungs, they merge 
smoothly into each other in parallel flows. invention. 
DETAILED DESCRIPTION OF PREFERRED 
EMBODIMENTS 
Referring now in detail to the drawing figures, wherein like 
reference numerals represent like parts throughout the several 
views, the present invention preferably is a method oflimiting 
flow turbulence in an energy efficient manner, and a device for 
same. A preferred method of present invention includes the 
steps of providing a flow merging device, splitting a first inlet 
flow at the flow merging device into a first branch and a 
The present invention is preferably a two-inlet, two-outlet 
tubular member, wherein vessels terminate at the inlet and 
outlet ports of the connection, the member so designed to 
60 avoid direct collision of the caval flows. The present invention 
facilitates minimal flow energy loss and provides preferably 
equal amounts of nutrient filled hepatic blood to both lungs. 
The invention can be tubular, and can take other shapes, 
such as elliptic, squared, hexagonal, octagonal, and triangu-
65 lar. 
The present connection need not necessarily be planar, as 
inlets and/or outlets can each be in different planes. The angle 
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between inlets, and the angle between outlets, need not be 180 
degrees, although that is shown in many of the Figs. Similarly, 
the angle between an inlet and outlet can be different than 90 
degrees. 
While the present device can be used in numerous environ-
ments, diameters for anatomically purposes are rarely equal. 
Preferably, the diameters of the inlets/outlets of the connec-
tion should match the vessels attached thereto. Diameter mis-
match between the device and the vessels can cause increases 
in power loss. 
The device is preferably an anatomical connection used for 
the heart, but it will be understood that the connection can be 
used in other parts of the body with various fluid flows. For 
example, the connection can be used where blood needs to be 
diverted either in the venous or arterial circulation. 
The present device can be used in conjunction with a pump. 
With a two inlet device, for example, by having a pump before 
one inlet to boost the flow, the flow from the other inlet will 
automatically be increased too, due to the suction effect at the 
outlet connections sites. 
The device can include fins/obstructions in the pathways 
that can be used to reduce secondary flow, swirl, and helicity. 
While the connection device can be used in both humans, 
and other animals, it can be used in non-anatomical flow 
environments, like engines, combustion, pipe lines, and 
plumbing. The connection device may also be used in non-
fluid or flow connections, for example, for electric currents, 
wave guides and optical connections. In such high frequency 
communication carrier embodiments (optical and electric), 
the invention can be, for example, be an optical booster, 
optical splitters, and wave guide splitter/connection. As such, 
the present device can be constructed of, among others, met-
als, glass, plastics, transparent materials in general, and insu-
lation materials (thermal, electromagnetic, and electric). 
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first connection outlet 60 the RPA path, and the second con-
nection outlet 80 the LPA path. 
Although the inlets 20, 40 are shown at 180 degrees from 
each other, and the outlets 60, 80 too shown at 180 degrees 
from each other, they need not be so orientated, nor in the 
same planes. The goal of the present invention is mainly to 
eliminate the region 90, which in prior art connections with 
the region where the inlet flows collide with one another. As 
shown in FIG. 8, the region 90 of the present invention is 
10 indeed not a part of the device 100, but an area that is designed 
around by the bifurcation of the inlet flow paths before reach-
ing such a region of intersection. 
The first connection inlet 20 comprises a first connection 
inlet chamber 24 prior to the inlet 20 splitting in a first outlet 
15 path 28 and a second outlet path 32. The second connection 
inlet 40 comprises a second connection inlet chamber 44 prior 
to the inlet 40 splitting in a first outlet path 48 and a second 
outlet path 52. Chambers 24, 44 are simply lengths of the 
inlets of the device 100 wherein the IVC/SVC flow has not yet 
20 been split. 
The first connection inlet 20 and the second connection 
inlet 40 preferably are in the same plane, and at 180 degrees 
from one another. Inlets 20, 40 further preferably have the 
same diameter as the vessels they are each attached to (which, 
25 in the case of IVC/SVC connections, are not the same), and 
split the flow between their respective outlet paths 28, 32 and 
48, 52 evenly. 
First outlet paths 28, 48 then merge to enable the combined 
flow to commonly exit first connection outlet 60. First con-
30 nection outlet 60 has a first outlet chamber 62 into which the 
outlet paths 28, 48 lead, prior to the flow exiting the outlet 60. 
The present device can be used in optical connections/ 35 
applications, for example, splitting optical fibers from one 
inlet to two outlets, where the second inlet is used to boost the 
power of the signal. Presently, an optical fiber signal can be 
boosted by having a y-shaped connection, with two inlets: 
one with a weak signal, another with a power boost input, and 40 
this amplifies the weak signal coming out of the one outlet. 
This is, for example, used to boost signals in transoceanic 
optical fibers. 
Second outlet paths 32, 52 merge to enable flow to exit 
second connection outlet 80. Second connection outlet 80 has 
a second outlet chamber 82 into which the outlet paths 32, 52 
lead, prior to the flow exiting the outlet 80. 
The first connection outlet 60 and the second connection 
outlet 80 preferably are in the same plane, and at 180 degrees 
from one another. Outlets 60, 80 further preferably have the 
same diameter. 
Thus, blood flow enters the connection 100 in from oppo-
site vessels, and exits in two other opposite vessels. The 
invention ofFIG. 8 is symmetrical about the x, y, and z planes, 
although the connection need not be so designed. Further, the 
paths 28, 32, 48, 52 are shown with uniform diameter along 
their length, and with each other, although the diameter of the 
paths 28, 32, 48, 52 need not be so uniform, nor do the 
FIGS. 8-20 show various preferred embodiments of the 
present invention 100. The embodiments of FIGS. 8-15 illus- 45 
trate tubular-like connection members, wherein the vessels 
attach directly to the inlets/outlets of the device. The present 
invention 100 of FIGS. 8-15 is a self-contained, tubular struc-
ture, wherein vessels terminate at the inlets/outlets, and blood 
flows within the device. FIGS. 16-20 illustrate another gen- 50 
era! embodiment of the present invention, wherein the device 
diameters of inlets and outlets 20, 40, 60, and 80. 
Indeed, FIG. 10 illustrates the present invention 100 with 
path diameters non-constant along the length of the paths 28, 
32, 48, 52. Changing path diameters changes the flow and 
pressure distribution. By increasing some path diameters and 
decreasing other path diameters, the blood can be more or less 
redirected where it is needed most. 
FIG. 9 illustrates an example of flow path through a pre-
is a center piece 200, being a flow merging device that pro-
vides an internal infrastructure or framework to bifurcate the 
flows of the IVC/SVC. The device 200 of FIGS. 16-20 com-
prises a connection system that allows blood flow to continue 
through connected vessels, and simply properly orients the 
vessels and flow therein. FIG. 19 illustrates an example of 
environment of use for the center piece embodiment 200 of 
the present invention of FIG. 18. The device of FIG. 20 is for 
use as a center piece graft in the case where there are two 
SVCs, for example, and the devices of FIGS. 18and19 do not 
work well. 
55 ferred embodiment of the present invention 100. As can be 
seen, at regions 64, 84 of merging flows, the split inlet flows 
mix with vectors of approximately same bearing, thus limit-
ing momentum loss and mixing. The arrows indicating flow 
lines in FIGS. 9, 13and15 are provided merely as examples, 
60 and it will be understood that the actual flow may differ both 
in direction, and in shown contour. 
The invention 100 of FIG. 8 preferably comprises a first 
connection inlet 20, a second connection inlet 40, a first 
connection outlet 60 and a second connection outlet 80. For 65 
ease of discussion only, the first connection inlet 20 could be 
for the SVC, the second connection inlet 40 for the IVC, the 
FIGS. 11and12 show other embodiments of the present 
invention 100, the device having two inlets 20, 40, and one 
outlet 60. FIG. 13 illustrates an example of flow path through 
a preferred embodiment of the present invention 100 having 
one inlet 40, and two outlets 60, 80. The embodiment of FIG. 
13 is a 90 degree connection, unlike the Y-connection, and 
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incorporates curvature for a smooth transition in the outlet 
direction. This embodiment can be used in the first stage 
Fontan surgery when connecting the SVC alone on the PAs. 
FIG. 14 is another embodiment of the invention, for 
example for a bilateral SVC, wherein the device 100 com-
prises three inlets, 20, 30 and 40. FIG. 15 is a variation on this 
design, having a cross-over bilateral SVC, providing a higher 
radius of curvature for the SVCs. 
As seen in FIGS. 8-20, the present invention 100 preferably 
comprises numerous beneficial geometries, including offset 10 
between the paths/vessels, paths/vessels that curve, and those 
that are not necessarily in the same plane, and paths/vessels 
entering and exiting with different diameters. 
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FIG. 24 illustrates pressure drop comparisons of the 
present invention and a one diameter offset reference model at 
different cardiac outputs. During exercise conditions the 
effect of high flow resistance or power loss is more apparent 
if pressure drop (combined static and dynamic) vs. cardiac 
output is plotted for this suggested TCPC anatomy and the 
one diameter offset reference model. Slopes of the curves in 
FIG. 24 give the equivalent flow resistance in the correspond-
ing TCPC. At high cardiac outputs, pressure drops are con-
siderable consuming the pressure head supplied by the heart. 
Low exercise capability of Fontan patients are already high-
lighted in several clinical publications. Embodiments of the 
present invention have 48%, 58%, and 61 % lower pressure 
drops at 2, 4 and 6 Umin cardiac outputs respectively. 
FIG. 25 shows dP difference between a patient with a 
non-optimal connection, and a preferred embodiment of the 
present invention. The dP's were found through computa-
tional fluid dynamic calculation. Since the slope of the 
present invention is much smaller than the anatomic, the 
pressure drops over the anatomic is much higher. 
The present invention also offers a controlled way of dis-
tributing the total cardiac output to both lungs. As the right 
lung is greater in size, more blood naturally flows to it. Such 
a fine distribution is not possible with the current surgical 
Recent studies on present anatomical TCPC models indi-
cate that the blood flow resistance through the TCPC can be 15 
quite significant for the configurations studied, comparable to 
the other major resistance sources of the body (like pulmo-
nary and vascular resistances). The TCPC flow resistance 
depends on the connection geometry like vessel sizes, diam-
eters, connection shape, flare, offset and stenosis. In FIG. 3, 20 
the resistance value for an intra-atrial Fontan anatomy is 
given which is only 56% lower than the systemic vascular 
resistance and 76% higher than the pulmonary vascular resis-
tance. This resistance value for the TCPC connection is cal-
culated from the measured pressure and flow rates of in vitro 
tests. Any reduction of TCPC resistance or equivalently 
hemodynamic power loss will enable higher flow rates, and 
reduce the work done by the single ventricle, and ultimately 
improve the quality oflife. Even a couple of percentage point 
improvements in hydrodynamic efficiency will lead to major 30 
impact as the heart operates continuously through life. 
25 techniques, but a prefabricated graft configuration of the 
present invention can facilitate any split based on the patient's 
specific needs. 
The present invention 100 is thus an approach to the Fontan 
connection in an effort to improve flow optimization and 
distribution. Experiments are showing that power loss and 
pressure drops across the connections between the present 
design and the vascular connections used in the Fontan opera-
tion could be significantly reduced, resulting in improved 
quality of life. 
The present invention can be formed of many materials, 
including biocompatible materials, although preferably, the 
device 100 is built by tissue-engineered material that can 
grow with the patient. Materials can include, for example, 
TCPC flows have been computationally and experimen-
tally studied through simplified models that incorporate 
increasingly complex anatomic features such as SVC/IVC 
flare, caval offset, pulmonary artery curvature and physi- 35 
ologic diameters. Models are valuable as they enable an 
essential understanding of the underlying fluid dynamics and 
facilitate isolation of specific hemodynamic phenomena that 
are integrated into complex 3D anatomic connection flow 
fields. 
Previous studies on a one diameter IVC/SVC caval offset 
reference TCPC model demonstrated its low hydrodynamic 
energy loss characteristics due to the stable buffer vortex 
located at the offset region. In this model, all vena cava and 
pulmonary artery branches have a constant diameter of 45 
13.335 mm, a dimension based on the chest MRI ofaneight-
year-old Fontan patient. The offset is defined as the distance 
between the caval axes. Larger offsets distances are surgically 
impractical to construct, but provide lower loss indices and 
can result in undesirable hepatic blood mixing or rather lack 50 
thereof since the blood in the offset region is rather stagnant. 
40 
homograft, autograft, allograft, plastics and biocompatible 
materials such as TEFLON, DACRON, and polytetetrafluo-
roethylene (PTFE). 
FIG. 21 is a CFD mid-plane of the device 100 of FIG. 8, 
showing in-plane velocity magnitudes shaded according to 
the scale on the light. FIG. 22 is a PIV mid-plane of the device 
100 ofFIG.10, showing in-plane velocity magnitudes shaded 55 
according to the scale on the right. 
FIG. 23 illustrates the hydrodynamic power loss compari-
sons of the present invention and one diameter offset refer-
ence model at 4 Umin cardiac output, where 40% comes in 
via the SVC and 60% via the IVC. The present invention is 60 
compared with this one diameter off set reference model. FIG. 
23 shows the power loss plots of both configurations for 
different flow splits. For 50/50 PA flow split, one embodiment 
of the present invention gives 17% lower power loss values 
compared to the reference conventional TCPC at 4 Umin. 65 
Improvements at higher cardiac outputs are higher, as dis-
cussed below. 
FIG. 8 illustrates an embodiment of the present invention 
100, being a most optimal configuration; however, this con-
figuration can not be used in all cases. The final stage or 
Norwood III (Fontan) operation is performed early in the 
patient's life; usually between 18-24 months of age. Patient 
growth naturally results in a size mismatch between the 
present connection and the vascular system. 
Therefore, the present invention should be formed of mate-
rial that would allow adaptation to patient size, but still allow 
for the power loss optimized streamlined flow, and ensure as 
close to equal distribution as possible of the nutrient-filled 
hepatic blood flow to both lungs, which has been shown to be 
very important in lung development. The connections of 
FIGS. 16-17 illustrate an embodiment of the invention 100 to 
address this issue. This allows for partially utilizing graft 
material and native blood vessels. The graft material will not 
grow; however, the native blood vessels completing the con-
nection are allowed to grow outwards. 
In cases where the SVC is too small for division and attach-
ment to the center-piece just described and shown in FIGS. 
16-17, a variant of the present invention, a center-piece con-
nection 200 was created, which allowed for splitting of the 
IVC and SVC flow. The SVC split is smaller, enabling direct 
attachment to the graft without creating stenotic areas at the 
SVC attachment site (FIGS. 18-20). 
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It is apparent that the various preferred embodiments of the 
present invention provide numerous advantages over the cur-
rent TCPC designs allowing for the combination ofIVC/SVC 
flows at angles greater than zero. For example, the embodi-
ment of the present invention as shown in FIG. 8 is advanta-
geous, for, among other reasons: 
16 
splitting a first inlet flow at the flow merging device into a 
first branch and a second branch; 
splitting a second inlet flow at the flow merging device into 
a first branch and a second branch; and 
merging the first branches of the first and second inlet flows 
together; wherein the flows in each of the first branches 
are substantially parallel at the site of merging. Nutrient filled hepatic blood equally distributed to both 
lungs. 
Streamlined flow reduces power losses significantly, which 
reduces the workload on the univentricular heart. 
No stagnant flow, which otherwise could cause thrombus 
formation. 
2. The method according to claim 1, further comprising 
merging the second branches of the first and second inlet 
10 flows together, wherein the flows in each of the second 
branches are substantially parallel at the site of merging. 
Negative pulmonary pressure during inspiration causes 
more efficient flow towards lungs than in other Fontan 
connections. This increases the flow, which in turn 15 
increases the cardiac output. Reduced cardiac output is 
the major mortality cause. 
3. The method according to claim 2, wherein the flow rates 
in the merged first branches and the merged second branches 
are substantially equal. 
4. The method according to claim 1, wherein the first inlet 
flow is a flow of blood. 
5. The method according to claim 4, further comprising 
directing the flow of the merged first branches to a lung. Suture lines kept at a minimum (only necessary to suture at 
inlets and outlets). 
Fast and easy to deploy. 
More adaptive to flow split changes than other configura-
tions. 
The embodiment of the present invention as shown in 
FIGS. 16-17 also has numerous advantages, including: 
6. The method according to claim 4, further comprising 
20 directing the flow of the merged second branches to a lung. 
7. The method according to claim 1, wherein the flow 
merging device comprises tissue-engineered material. 
Nutrient filled hepatic blood equally distributed to both 
lungs. 
8. A device for merging at least two inlet flows, and there-
after directing portions of each inlet flow to at least two outlets 
25 in an energy efficient manner, the device comprising: 
Streamlined flow reduces power losses significantly, which 
reduces the workload on the univentricular heart. 
No stagnant flow, which otherwise would cause thrombus 
formation. 
Negative pulmonary pressure during inspiration causes 
more efficient flow towards lungs than in other Fontan 
connections. This increases the flow, which in turn 
increases the cardiac output. Reduced cardiac output is 
the major mortality cause. 
More adaptive to flow split changes than other configura-
tions. 




The embodiment of the present invention as shown in 40 
FIGS. 18-20 has its own advantages, including: 
a first connection inlet to receive a first liquid flow and 
guide the first liquid flow toward a first outlet and a 
second outlet; 
a second connection inlet to receive a second liquid flow 
and guide the second liquid flow toward the first outlet 
and the second outlet; 
a first outlet chamber, in liquid communication with the 
first outlet, sized and shape to receive a portion of the 
first liquid flow and a portion of the second liquid flow 
and merge the flows in a substantially parallel fashion 
for provision to the first outlet; and 
a second outlet chamber, in liquid communication with the 
second outlet, sized and shape to receive a portion of the 
first liquid flow and a portion of the second liquid flow 
and merge the flows in a substantially parallel fashion 
for provision to the second outlet. 
Nutrient filled hepatic blood equally distributed to both 
lungs. 
Streamlined flow reduces power losses significantly, which 
reduces the workload on the univentricular heart. 
9. The device of claim 8, wherein the first and second 
outlets are sized and shaped to have substantially equal flow 
45 
rates therethrough. 
10. The device of claim 8, wherein the device is for use 
where at least one of the inlet flows is a flow of blood. 
No stagnant flow, which otherwise would cause thrombus 
formation. 
Negative pulmonary pressure during inspiration causes 
more efficient flow towards lungs than in other Fontan 
connections. This increases the flow, which in turn 50 
increases the cardiac output. Reduced cardiac output is 
the major mortality cause. 
More adaptive to flow split changes than other configura-
tions. 
Connection and vessel diameters will grow with patient 55 
growth. 
In cases where SVC diameter is too small to split, this can 
be used instead of the graft shown in FIGS. 16-17. 
While the invention has been disclosed in its preferred 
forms, it will be apparent to those skilled in the art that many 60 
modifications, additions, and deletions can be made therein 
without departing from the spirit and scope of the invention 
and its equivalents as set forth in the following claims. 
11. The device of claim 10, wherein at least one of the 
outlets directs flow to a lung. 
12. The device of claim 8, wherein the device comprises 
tissue-engineered material. 
13. A method for limiting venous blood flow disturbance 
from the systemic to the pulmonary circulation in an energy 
efficient manner comprising: 
providing a flow merging device; 
splitting the IVC flow at the flow merging device into a first 
branch and a second branch; 
splitting the SVC flow at the flow merging device into a first 
branch and a second branch; and 
merging the first branches of the IVC and SVC flows 
together; 
wherein the flows in each of the first branches are substan-
tially parallel at the site of merging. 
What is claimed is: 
1. A method for limiting flow disturbance in an energy 
efficient manner comprising: 
providing a flow merging device; 
14. The method according to claim 13, further comprising 
65 merging the second branches of the IVC and SVC flows 
together, wherein the flows in each of the second branches are 
substantially parallel at the site of merging. 
US 7,811,244 B2 
17 
15. The method according to claim 14, wherein the flow 
rates in the merged first branches and the merged second 
branches are substantially equal. 
16. The method according to claim 14, further comprising 
directing the flow of the merged first branches to a lung. 
17. The method according to claim 14, further comprising 
directing the flow of the merged second branches to a lung. 
18. The method according to claim 13, wherein the flow 
merging device comprises tissue-engineered material. 
19. A method of performing a surgical procedure on the 10 
heart of a patient comprising: 
providing a flow merging device; 
splitting the IVC flow at the flow merging device into a first 
branch and a second branch; 
splitting the SVC flow at the flow merging device into a first 15 
branch and a second branch; and 
merging the first branches of the IVC and SVC flows 
together; wherein the flows in each of the first branches 
are substantially parallel at the site of merging. 
20. The method according to claim 19, wherein the flow 20 
merging device comprises: 
an IVC inlet at which the IVC is connected to the flow 
merging device; 
a SVC inlet at which the SVC is connected to the flow 
merging device; 25 
a first outlet at which the first branches of the IVC and SVC 
flows combine; and 
a second outlet at which the second branches of the IVC 
and SVC flows combine. 
21. A device for combining the flow of the IVC and the 30 
SVC in an energy efficient manner, and thereafter directing 
the combined flow to the lungs, the device comprising: 
an IVC inlet at which the IVC is connected, the IVC inlet 
splitting a portion of the IVC flow between a first branch 
and a second branch; 35 
a SVC inlet at which the SVC is connected, the SVC inlet 
splitting a portion of the SVC flow between a first branch 
and a second branch; 
18 
a first pulmonary outlet at which the first branches of the 
IVC and SVC flows combine, the first pulmonary outlet 
being in liquid communication with a first outlet cham-
ber having opposing curved features that combine the 
IVC and SVC flows and enable the combined IVC-SVC 
flows to commonly exit the first lung outlet; and 
a second pulmonary outlet at which the second branches of 
the IVC and SVC flows combine, the second pulmonary 
outlet being in liquid communication with a second out-
let chamber having opposing curved features that com-
bine the IVC and SVC flows and enable the combined 
IVC-SVC flows to commonly exit the second lung out-
let, 
wherein the flows in each of the first branches and second 
branches are substantially parallel at the sites of com-
bining the flows. 
22. A method of using a device for combining the flow of 
the IVC and the SVC, and thereafter directing the combined 
flow to the lungs, the method comprising: 
providing a device, the device comprising: 
an IVC inlet at which the IVC is connected, the IVC inlet 
splitting a portion of the IVC flow between a first 
branch and a second branch; 
a SVC inlet at which the SVC is connected, the SVC 
inlet splitting a portion of the SVC flow between a first 
branch and a second branch; 
a first pulmonary outlet at which the first branches of the 
IVC and SVC flows combine; and 
a second pulmonary outlet at which the second branches 
of the IVC and SVC flows combine, 
wherein the flows in each of the first branches and sec-
ond branches are substantially parallel at the sites of 
combining the flows; 
flowing a liquid through the device; and 
using the device ex vivo. 
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